Equities Analysts Offer Predictions for Knight Therapeutics Inc’s Q1 2017 Earnings (GUD)

Knight Therapeutics Inc (TSE:GUD) – Analysts at Cormark reduced their Q1 2017 earnings estimates for shares of Knight Therapeutics in a research report issued to clients and investors on Thursday. Cormark analyst D. Novak now forecasts that the brokerage will post earnings of $0.02 per share for the quarter, down from their previous estimate of $0.03. Cormark also issued estimates for Knight Therapeutics’ Q4 2017 earnings at $0.05 EPS and FY2017 earnings at $0.21 EPS.

Your IP Address:

Several other equities research analysts have also recently weighed in on GUD. National Bank Financial reiterated an “outperform market weight” rating on shares of Knight Therapeutics in a report on Thursday, March 16th. Scotiabank increased their price objective on Knight Therapeutics from C$10.50 to C$11.00 and gave the stock an “outperform” rating in a report on Friday. TD Securities reiterated a “buy” rating and issued a C$12.50 price objective on shares of Knight Therapeutics in a report on Monday. Mackie cut Knight Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from C$12.00 to C$10.75 in a report on Wednesday, January 4th. Finally, CIBC dropped their price objective on Knight Therapeutics from C$13.00 to C$9.80 in a report on Friday, January 13th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of C$11.16.

Shares of Knight Therapeutics (TSE:GUD) opened at 10.10 on Monday. The stock has a 50 day moving average of $10.56 and a 200 day moving average of $9.93. The firm has a market cap of $1.34 billion and a price-to-earnings ratio of 71.13. Knight Therapeutics has a 52-week low of $7.20 and a 52-week high of $11.03.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2024319/equities-analysts-offer-predictions-for-knight-therapeutics-incs-q1-2017-earnings-gud.html

Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.